| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| 2413.T - M3, Inc. | HOLD | 0 @ JPY 13.7687 | JPY 0 | The current share valuation price of 2413.T based on adjusted close was JPY 13.7687. The average price that 2413.T shares were previous bought at was JPY 14.2637. The current market price is -3.5% lower than average price they were purchased at. The value of the holding in 2413.T has increased by JPY 649 (USD $4) compared to the previous valuation of M3, Inc. however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| 4151.T - Kyowa Kirin Co., Ltd. | HOLD | 0 @ JPY 15.7324 | JPY 0 | The current share valuation price of 4151.T based on adjusted close was JPY 15.7324. The average price that 4151.T shares were previous bought at was JPY 15.513. The current market price is 1.4% higher than average price they were purchased at. The value of the holding in 4151.T has fallen by JPY 7,264 (USD $47) compared to the previous valuation of Kyowa Kirin Co., Ltd. |
| 4502.T - Takeda Pharmaceutical Company Limited | HOLD | 0 @ JPY 27.1479 | JPY 0 | The current share valuation price of 4502.T based on adjusted close was JPY 27.1479. The average price that 4502.T shares were previous bought at was JPY 28.7966. The current market price is -5.7% lower than average price they were purchased at. The value of the holding in 4502.T has fallen by JPY 4,833 (USD $31) compared to the previous valuation of Takeda Pharmaceutical Company Limited |
| 4503.T - Astellas Pharma Inc. | HOLD | 0 @ JPY 11.4609 | JPY 0 | The current share valuation price of 4503.T based on adjusted close was JPY 11.4609. The average price that 4503.T shares were previous bought at was JPY 10.6945. The current market price is 7.2% higher than average price they were purchased at. The value of the holding in 4503.T has increased by JPY 12,717 (USD $83) compared to the previous valuation of Astellas Pharma Inc. however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| 4507.T - Shionogi & Co., Ltd. | HOLD | 0 @ JPY 17.1833 | JPY 0 | The current share valuation price of 4507.T based on adjusted close was JPY 17.1833. The average price that 4507.T shares were previous bought at was JPY 16.8344. The current market price is 2.1% higher than average price they were purchased at. The value of the holding in 4507.T has increased by JPY 2,428 (USD $16) compared to the previous valuation of Shionogi & Co., Ltd. however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| 4519.T - Chugai Pharmaceutical Co., Ltd. | HOLD | 0 @ JPY 46.9863 | JPY 0 | The current share valuation price of 4519.T based on adjusted close was JPY 46.9863. The average price that 4519.T shares were previous bought at was JPY 45.8615. The current market price is 2.5% higher than average price they were purchased at. The value of the holding in 4519.T has fallen by JPY 172,486 (USD $1,121) compared to the previous valuation of Chugai Pharmaceutical Co., Ltd. |
| 4523.T - Eisai Co., Ltd. | HOLD | 0 @ JPY 28.5111 | JPY 0 | The current share valuation price of 4523.T based on adjusted close was JPY 28.5111. The average price that 4523.T shares were previous bought at was JPY 30.3993. The current market price is -6.2% lower than average price they were purchased at. The value of the holding in 4523.T has fallen by JPY 13,531 (USD $88) compared to the previous valuation of Eisai Co., Ltd. |
| 4543.T - Terumo Corporation | HOLD | 0 @ JPY 16.3686 | JPY 0 | The current share valuation price of 4543.T based on adjusted close was JPY 16.3686. The average price that 4543.T shares were previous bought at was JPY 16.7591. The current market price is -2.3% lower than average price they were purchased at. The value of the holding in 4543.T has increased by JPY 2,090 (USD $14) compared to the previous valuation of Terumo Corporation however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| 4568.T - Daiichi Sankyo Company, Limited | HOLD | 0 @ JPY 21.4548 | JPY 0 | The current share valuation price of 4568.T based on adjusted close was JPY 21.4548. The average price that 4568.T shares were previous bought at was JPY 27.6546. The current market price is -22.4% lower than average price they were purchased at. The value of the holding in 4568.T has fallen by JPY 139,499 (USD $907) compared to the previous valuation of Daiichi Sankyo Company, Limited |
| 4578.T - Otsuka Holdings Co., Ltd. | HOLD | 0 @ JPY 53.1273 | JPY 0 | The current share valuation price of 4578.T based on adjusted close was JPY 53.1273. The average price that 4578.T shares were previous bought at was JPY 55.5796. The current market price is -4.4% lower than average price they were purchased at. The value of the holding in 4578.T has fallen by JPY 13,725 (USD $89) compared to the previous valuation of Otsuka Holdings Co., Ltd. |
| 6869.T - Sysmex Corporation | HOLD | 0 @ JPY 10.8313 | JPY 0 | The current share valuation price of 6869.T based on adjusted close was JPY 10.8313. The average price that 6869.T shares were previous bought at was JPY 12.5573. The current market price is -13.7% lower than average price they were purchased at. The value of the holding in 6869.T has increased by JPY 27,378 (USD $178) compared to the previous valuation of Sysmex Corporation however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| 7733.T - Olympus Corporation | HOLD | 0 @ JPY 13.5512 | JPY 0 | The current share valuation price of 7733.T based on adjusted close was JPY 13.5512. The average price that 7733.T shares were previous bought at was JPY 12.6166. The current market price is 7.4% higher than average price they were purchased at. The value of the holding in 7733.T has increased by JPY 32,348 (USD $210) compared to the previous valuation of Olympus Corporation however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| 7741.T - HOYA Corporation | HOLD | 0 @ JPY 162.29 | JPY 0 | The current share valuation price of 7741.T based on adjusted close was JPY 162.29. The average price that 7741.T shares were previous bought at was JPY 135.742. The current market price is 19.6% higher than average price they were purchased at. The value of the holding in 7741.T has fallen by JPY 27,132 (USD $176) compared to the previous valuation of HOYA Corporation |
| A - Agilent Technologies Inc | HOLD | 0 @ USD 146.36 | USD 0 | The current share valuation price of A based on adjusted close was USD 146.36. The average price that A shares were previous bought at was USD 135.277. The current market price is 8.2% higher than average price they were purchased at. The value of the holding in A has fallen by USD 33,677 compared to the previous valuation of Agilent Technologies Inc |
| ABBV - AbbVie Inc | HOLD | 0 @ USD 218.71 | USD 0 | The current share valuation price of ABBV based on adjusted close was USD 218.71. The average price that ABBV shares were previous bought at was USD 204.201. The current market price is 7.1% higher than average price they were purchased at. The value of the holding in ABBV has fallen by USD 56,564 compared to the previous valuation of AbbVie Inc |
| ABT - Abbott Laboratories | HOLD | 0 @ USD 125.89 | USD 0 | The current share valuation price of ABT based on adjusted close was USD 125.89. The average price that ABT shares were previous bought at was USD 132.169. The current market price is -4.8% lower than average price they were purchased at. The value of the holding in ABT has fallen by USD 38,330 compared to the previous valuation of Abbott Laboratories |
| ALC.SW - | HOLD | 0 @ CHF 73.7801 | CHF 0 | The current share valuation price of ALC.SW based on adjusted close was CHF 73.7801. The average price that ALC.SW shares were previous bought at was CHF 77.9566. The current market price is -5.4% lower than average price they were purchased at. The value of the holding in ALC.SW has increased by CHF 63,361 (USD $78,506) compared to the previous valuation of however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| ALGN - Align Technology Inc | HOLD | 0 @ USD 138.23 | USD 0 | The current share valuation price of ALGN based on adjusted close was USD 138.23. The average price that ALGN shares were previous bought at was USD 135.875. The current market price is 1.7% higher than average price they were purchased at. The value of the holding in ALGN has increased by USD 6,228 compared to the previous valuation of Align Technology Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| ALNY - Alnylam Pharmaceuticals Inc | HOLD | 0 @ USD 441.7 | USD 0 | The current share valuation price of ALNY based on adjusted close was USD 441.7. The average price that ALNY shares were previous bought at was USD 414.737. The current market price is 6.5% higher than average price they were purchased at. The value of the holding in ALNY has fallen by USD 7,626 compared to the previous valuation of Alnylam Pharmaceuticals Inc |
| AMGN - Amgen Inc | HOLD | 0 @ USD 323.66 | USD 0 | The current share valuation price of AMGN based on adjusted close was USD 323.66. The average price that AMGN shares were previous bought at was USD 289.67. The current market price is 11.7% higher than average price they were purchased at. The value of the holding in AMGN has increased by USD 94,994 compared to the previous valuation of Amgen Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| ARGX.BR - Argenx SE | HOLD | 0 @ EUR 860.445 | EUR 0 | The current share valuation price of ARGX.BR based on adjusted close was EUR 860.445. The average price that ARGX.BR shares were previous bought at was EUR 714.954. The current market price is 20.3% higher than average price they were purchased at. The value of the holding in ARGX.BR has increased by EUR 30,672 (USD $35,407) compared to the previous valuation of Argenx SE however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| AZN.L - AstraZeneca PLC | HOLD | 0 @ GBP 172.587 | GBP 0 | The current share valuation price of AZN.L based on adjusted close was GBP 172.587. The average price that AZN.L shares were previous bought at was GBP 133.937. The current market price is 28.9% higher than average price they were purchased at. The value of the holding in AZN.L has increased by GBP 518,498 (USD $681,445) compared to the previous valuation of AstraZeneca PLC however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| BAX - Baxter International Inc | HOLD | 0 @ USD 17.75 | USD 0 | The current share valuation price of BAX based on adjusted close was USD 17.75. The average price that BAX shares were previous bought at was USD 22.3875. The current market price is -20.7% lower than average price they were purchased at. The value of the holding in BAX has fallen by USD 2,606 compared to the previous valuation of Baxter International Inc |
| BAYN.DE - Bayer AG | HOLD | 0 @ EUR 30.5982 | EUR 0 | The current share valuation price of BAYN.DE based on adjusted close was EUR 30.5982. The average price that BAYN.DE shares were previous bought at was EUR 31.1449. The current market price is -1.8% lower than average price they were purchased at. The value of the holding in BAYN.DE has increased by EUR 8,512 (USD $9,826) compared to the previous valuation of Bayer AG however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| BDX - Becton Dickinson and Company | HOLD | 0 @ USD 181.64 | USD 0 | The current share valuation price of BDX based on adjusted close was USD 181.64. The average price that BDX shares were previous bought at was USD 182.841. The current market price is -0.7% lower than average price they were purchased at. The value of the holding in BDX has increased by USD 22,689 compared to the previous valuation of Becton Dickinson and Company however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| BIIB - Biogen Inc | HOLD | 0 @ USD 156.26 | USD 0 | The current share valuation price of BIIB based on adjusted close was USD 156.26. The average price that BIIB shares were previous bought at was USD 144.991. The current market price is 7.8% higher than average price they were purchased at. The value of the holding in BIIB has increased by USD 2,186 compared to the previous valuation of Biogen Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| BIM.PA - BioMerieux | HOLD | 0 @ EUR 122.97 | EUR 0 | The current share valuation price of BIM.PA based on adjusted close was EUR 122.97. The average price that BIM.PA shares were previous bought at was EUR 129.948. The current market price is -5.4% lower than average price they were purchased at. The value of the holding in BIM.PA has fallen by EUR 668 (USD $771) compared to the previous valuation of BioMerieux |
| BMRN - Biomarin Pharmaceutical Inc | HOLD | 0 @ USD 52.6699 | USD 0 | The current share valuation price of BMRN based on adjusted close was USD 52.6699. The average price that BMRN shares were previous bought at was USD 56.2324. The current market price is -6.3% lower than average price they were purchased at. The value of the holding in BMRN has increased by USD 5,095 compared to the previous valuation of Biomarin Pharmaceutical Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| BMY - Bloomsbury Publishing Plc | HOLD | 0 @ USD 47.26 | USD 0 | The current share valuation price of BMY based on adjusted close was USD 47.26. The average price that BMY shares were previous bought at was USD 47.1527. The current market price is 0.2% higher than average price they were purchased at. The value of the holding in BMY has increased by USD 48,980 compared to the previous valuation of Bloomsbury Publishing Plc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| BSX - Boston Scientific Corporation | HOLD | 0 @ USD 100.91 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 100.91. The average price that BSX shares were previous bought at was USD 101.398. The current market price is -0.5% lower than average price they were purchased at. The value of the holding in BSX has increased by USD 28,724 compared to the previous valuation of Boston Scientific Corporation however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| BSX - MULSTRXSSXIMETFP | HOLD | 0 @ USD 100.91 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 100.91. The average price that BSX shares were previous bought at was USD 101.398. The current market price is -0.5% lower than average price they were purchased at. The value of the holding in BSX has increased by USD 28,724 compared to the previous valuation of MULSTRXSSXIMETFP however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| CAH - Cardinal Health Inc | HOLD | 0 @ USD 205.43 | USD 0 | The current share valuation price of CAH based on adjusted close was USD 205.43. The average price that CAH shares were previous bought at was USD 165.397. The current market price is 24.2% higher than average price they were purchased at. The value of the holding in CAH has increased by USD 130,191 compared to the previous valuation of Cardinal Health Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| CI - Cigna Corp | HOLD | 0 @ USD 258.16 | USD 0 | The current share valuation price of CI based on adjusted close was USD 258.16. The average price that CI shares were previous bought at was USD 292.391. The current market price is -11.7% lower than average price they were purchased at. The value of the holding in CI has fallen by USD 276,085 compared to the previous valuation of Cigna Corp |
| CNC - Concurrent Technologies Plc | HOLD | 0 @ USD 34.25 | USD 0 | The current share valuation price of CNC based on adjusted close was USD 34.25. The average price that CNC shares were previous bought at was USD 39.361. The current market price is -13.0% lower than average price they were purchased at. The value of the holding in CNC has fallen by USD 386,164 compared to the previous valuation of Concurrent Technologies Plc |
| COH.AX - | HOLD | 0 @ AUD 184.938 | AUD 0 | The current share valuation price of COH.AX based on adjusted close was AUD 184.938. The average price that COH.AX shares were previous bought at was AUD 185.498. The current market price is -0.3% lower than average price they were purchased at. The value of the holding in COH.AX has increased by AUD 14,612 (USD $9,501) compared to the previous valuation of however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| COLO-B.CO - | HOLD | 0 @ DKK 92.8096 | DKK 0 | The current share valuation price of COLO-B.CO based on adjusted close was DKK 92.8096. The average price that COLO-B.CO shares were previous bought at was DKK 92.4839. The current market price is 0.4% higher than average price they were purchased at. The value of the holding in COLO-B.CO has fallen by DKK 32,210 (USD $4,980) compared to the previous valuation of |
| COO - The Cooper Companies, Inc. Common Stock | HOLD | 0 @ USD 70.72 | USD 0 | The current share valuation price of COO based on adjusted close was USD 70.72. The average price that COO shares were previous bought at was USD 70.1887. The current market price is 0.8% higher than average price they were purchased at. The value of the holding in COO has increased by USD 2,446 compared to the previous valuation of The Cooper Companies, Inc. Common Stock however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| COR - Cencora Inc. | HOLD | 0 @ USD 364.65 | USD 0 | The current share valuation price of COR based on adjusted close was USD 364.65. The average price that COR shares were previous bought at was USD 318.212. The current market price is 14.6% higher than average price they were purchased at. The value of the holding in COR has increased by USD 192,424 compared to the previous valuation of Cencora Inc. however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| CSL.AX - | HOLD | 0 @ AUD 116.587 | AUD 0 | The current share valuation price of CSL.AX based on adjusted close was AUD 116.587. The average price that CSL.AX shares were previous bought at was AUD 132.252. The current market price is -11.8% lower than average price they were purchased at. The value of the holding in CSL.AX has increased by AUD 6,914 (USD $4,496) compared to the previous valuation of however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| CVS - CVS Health Corp | HOLD | 0 @ USD 77.54 | USD 0 | The current share valuation price of CVS based on adjusted close was USD 77.54. The average price that CVS shares were previous bought at was USD 68.7988. The current market price is 12.7% higher than average price they were purchased at. The value of the holding in CVS has fallen by USD 85,771 compared to the previous valuation of CVS Health Corp |
| DEMANT.CO - | HOLD | 0 @ DKK 34.3281 | DKK 0 | The current share valuation price of DEMANT.CO based on adjusted close was DKK 34.3281. The average price that DEMANT.CO shares were previous bought at was DKK 35.7818. The current market price is -4.1% lower than average price they were purchased at. The value of the holding in DEMANT.CO has increased by DKK 3,726 (USD $576) compared to the previous valuation of however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| DGX - Quest Diagnostics Incorporated | HOLD | 0 @ USD 184.31 | USD 0 | The current share valuation price of DGX based on adjusted close was USD 184.31. The average price that DGX shares were previous bought at was USD 180.581. The current market price is 2.1% higher than average price they were purchased at. The value of the holding in DGX has increased by USD 10,490 compared to the previous valuation of Quest Diagnostics Incorporated however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| DHR - Danaher Corporation | HOLD | 0 @ USD 211.17 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 211.17. The average price that DHR shares were previous bought at was USD 198.694. The current market price is 6.3% higher than average price they were purchased at. The value of the holding in DHR has increased by USD 37,607 compared to the previous valuation of Danaher Corporation however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| DHR - Danaher Corporation | HOLD | 0 @ USD 211.17 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 211.17. The average price that DHR shares were previous bought at was USD 198.694. The current market price is 6.3% higher than average price they were purchased at. The value of the holding in DHR has increased by USD 37,607 compared to the previous valuation of Danaher Corporation however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| DIM.PA - Sartorius Stedim Biotech | HOLD | 0 @ EUR 216.15 | EUR 0 | The current share valuation price of DIM.PA based on adjusted close was EUR 216.15. The average price that DIM.PA shares were previous bought at was EUR 220.877. The current market price is -2.1% lower than average price they were purchased at. The value of the holding in DIM.PA has fallen by EUR 2,583 (USD $2,982) compared to the previous valuation of Sartorius Stedim Biotech |
| DVA - DaVita HealthCare Partners Inc | HOLD | 0 @ USD 120.17 | USD 0 | The current share valuation price of DVA based on adjusted close was USD 120.17. The average price that DVA shares were previous bought at was USD 128.185. The current market price is -6.3% lower than average price they were purchased at. The value of the holding in DVA has fallen by USD 6,878 compared to the previous valuation of DaVita HealthCare Partners Inc |
| DXCM - DexCom Inc | HOLD | 0 @ USD 54.84 | USD 0 | The current share valuation price of DXCM based on adjusted close was USD 54.84. The average price that DXCM shares were previous bought at was USD 71.3092. The current market price is -23.1% lower than average price they were purchased at. The value of the holding in DXCM has fallen by USD 1,638 compared to the previous valuation of DexCom Inc |
| EL.PA - EssilorLuxottica SA | HOLD | 0 @ EUR 360.02 | EUR 0 | The current share valuation price of EL.PA based on adjusted close was EUR 360.02. The average price that EL.PA shares were previous bought at was EUR 319.13. The current market price is 12.8% higher than average price they were purchased at. The value of the holding in EL.PA has increased by EUR 27,207 (USD $31,407) compared to the previous valuation of EssilorLuxottica SA however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| ELV - Elevance Health Inc | HOLD | 0 @ USD 303.78 | USD 0 | The current share valuation price of ELV based on adjusted close was USD 303.78. The average price that ELV shares were previous bought at was USD 381.913. The current market price is -20.5% lower than average price they were purchased at. The value of the holding in ELV has fallen by USD 571,816 compared to the previous valuation of Elevance Health Inc |
| ELV - Elevance Health Inc | HOLD | 0 @ USD 303.78 | USD 0 | The current share valuation price of ELV based on adjusted close was USD 303.78. The average price that ELV shares were previous bought at was USD 381.913. The current market price is -20.5% lower than average price they were purchased at. The value of the holding in ELV has fallen by USD 571,816 compared to the previous valuation of Elevance Health Inc |
| ERF.PA - Eurofins Scientific SE | HOLD | 0 @ EUR 66.9698 | EUR 0 | The current share valuation price of ERF.PA based on adjusted close was EUR 66.9698. The average price that ERF.PA shares were previous bought at was EUR 54.3413. The current market price is 23.2% higher than average price they were purchased at. The value of the holding in ERF.PA has fallen by EUR 1,918 (USD $2,214) compared to the previous valuation of Eurofins Scientific SE |
| EW - Edwards Lifesciences Corp | HOLD | 0 @ USD 84.08 | USD 0 | The current share valuation price of EW based on adjusted close was USD 84.08. The average price that EW shares were previous bought at was USD 78.2923. The current market price is 7.4% higher than average price they were purchased at. The value of the holding in EW has increased by USD 84,429 compared to the previous valuation of Edwards Lifesciences Corp however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| FME.DE - Fresenius Medical Care AG | HOLD | 0 @ EUR 47.5023 | EUR 0 | The current share valuation price of FME.DE based on adjusted close was EUR 47.5023. The average price that FME.DE shares were previous bought at was EUR 51.4499. The current market price is -7.7% lower than average price they were purchased at. The value of the holding in FME.DE has fallen by EUR 2,156 (USD $2,489) compared to the previous valuation of Fresenius Medical Care AG |
| FPH.NZ - | HOLD | 0 @ NZD 21.4577 | NZD 0 | The current share valuation price of FPH.NZ based on adjusted close was NZD 21.4577. The average price that FPH.NZ shares were previous bought at was NZD 21.107. The current market price is 1.7% higher than average price they were purchased at. The value of the holding in FPH.NZ has fallen by NZD 1,735 (USD $976) compared to the previous valuation of |
| FRE.DE - Fresenius SE & Co KGaA | HOLD | 0 @ EUR 55.3193 | EUR 0 | The current share valuation price of FRE.DE based on adjusted close was EUR 55.3193. The average price that FRE.DE shares were previous bought at was EUR 52.4661. The current market price is 5.4% higher than average price they were purchased at. The value of the holding in FRE.DE has increased by EUR 1,688 (USD $1,949) compared to the previous valuation of Fresenius SE & Co KGaA however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| GALD.SW - | HOLD | 0 @ CHF 182.652 | CHF 0 | The current share valuation price of GALD.SW based on adjusted close was CHF 182.652. The average price that GALD.SW shares were previous bought at was CHF 173.378. The current market price is 5.3% higher than average price they were purchased at. The value of the holding in GALD.SW has increased by CHF 10,779 (USD $13,355) compared to the previous valuation of however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| GEHC - GE HealthCare Technologies Inc. | HOLD | 0 @ USD 73.48 | USD 0 | The current share valuation price of GEHC based on adjusted close was USD 73.48. The average price that GEHC shares were previous bought at was USD 78.2367. The current market price is -6.1% lower than average price they were purchased at. The value of the holding in GEHC has increased by USD 4,004 compared to the previous valuation of GE HealthCare Technologies Inc. however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| GILD - Guild Esports Plc | HOLD | 0 @ USD 118.15 | USD 0 | The current share valuation price of GILD based on adjusted close was USD 118.15. The average price that GILD shares were previous bought at was USD 115.808. The current market price is 2.0% higher than average price they were purchased at. The value of the holding in GILD has fallen by USD 104,689 compared to the previous valuation of Guild Esports Plc |
| GMAB.CO - | HOLD | 0 @ DKK 290.011 | DKK 0 | The current share valuation price of GMAB.CO based on adjusted close was DKK 290.011. The average price that GMAB.CO shares were previous bought at was DKK 284.143. The current market price is 2.1% higher than average price they were purchased at. The value of the holding in GMAB.CO has increased by DKK 77,054 (USD $11,912) compared to the previous valuation of however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| GRF.MC - Grifols SA | HOLD | 0 @ EUR 12.3836 | EUR 0 | The current share valuation price of GRF.MC based on adjusted close was EUR 12.3836. The average price that GRF.MC shares were previous bought at was EUR 13.372. The current market price is -7.4% lower than average price they were purchased at. The value of the holding in GRF.MC has increased by EUR 7,782 (USD $8,983) compared to the previous valuation of Grifols SA however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| GSK.L - GlaxoSmithKline PLC | HOLD | 0 @ GBP 23.2991 | GBP 0 | The current share valuation price of GSK.L based on adjusted close was GBP 23.2991. The average price that GSK.L shares were previous bought at was GBP 21.6478. The current market price is 7.6% higher than average price they were purchased at. The value of the holding in GSK.L has increased by GBP 3,163 (USD $4,157) compared to the previous valuation of GlaxoSmithKline PLC however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| HCA - HCA Holdings Inc | HOLD | 0 @ USD 459.3 | USD 0 | The current share valuation price of HCA based on adjusted close was USD 459.3. The average price that HCA shares were previous bought at was USD 436.774. The current market price is 5.2% higher than average price they were purchased at. The value of the holding in HCA has fallen by USD 67,803 compared to the previous valuation of HCA Holdings Inc |
| HIK.L - | HOLD | 0 @ GBP 20.4459 | GBP 0 | The current share valuation price of HIK.L based on adjusted close was GBP 20.4459. The average price that HIK.L shares were previous bought at was GBP 24.113. The current market price is -15.2% lower than average price they were purchased at. The value of the holding in HIK.L has fallen by GBP 3,925 (USD $5,159) compared to the previous valuation of |
| HLN.L - Haleon PLC | HOLD | 0 @ GBP 4.77422 | GBP 0 | The current share valuation price of HLN.L based on adjusted close was GBP 4.77422. The average price that HLN.L shares were previous bought at was GBP 4.94029. The current market price is -3.4% lower than average price they were purchased at. The value of the holding in HLN.L has increased by GBP 4,262 (USD $5,601) compared to the previous valuation of Haleon PLC however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| HOLX - Hologic Inc | HOLD | 0 @ USD 74.3 | USD 0 | The current share valuation price of HOLX based on adjusted close was USD 74.3. The average price that HOLX shares were previous bought at was USD 70.0245. The current market price is 6.1% higher than average price they were purchased at. The value of the holding in HOLX has increased by USD 17,809 compared to the previous valuation of Hologic Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| HUM - Hummingbird Resources PLC | HOLD | 0 @ USD 238.42 | USD 0 | The current share valuation price of HUM based on adjusted close was USD 238.42. The average price that HUM shares were previous bought at was USD 302.069. The current market price is -21.1% lower than average price they were purchased at. The value of the holding in HUM has fallen by USD 250,581 compared to the previous valuation of Hummingbird Resources PLC |
| HUM - Humana Inc | HOLD | 0 @ USD 238.42 | USD 0 | The current share valuation price of HUM based on adjusted close was USD 238.42. The average price that HUM shares were previous bought at was USD 302.069. The current market price is -21.1% lower than average price they were purchased at. The value of the holding in HUM has fallen by USD 250,581 compared to the previous valuation of Humana Inc |
| IDXX - IDEXX Laboratories Inc | HOLD | 0 @ USD 709.59 | USD 0 | The current share valuation price of IDXX based on adjusted close was USD 709.59. The average price that IDXX shares were previous bought at was USD 606.673. The current market price is 17.0% higher than average price they were purchased at. The value of the holding in IDXX has increased by USD 17,950 compared to the previous valuation of IDEXX Laboratories Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| ILMN - Illumina Inc | HOLD | 0 @ USD 121.72 | USD 0 | The current share valuation price of ILMN based on adjusted close was USD 121.72. The average price that ILMN shares were previous bought at was USD 100.693. The current market price is 20.9% higher than average price they were purchased at. The value of the holding in ILMN has fallen by USD 555 compared to the previous valuation of Illumina Inc |
| INCY - Incyte Corporation | HOLD | 0 @ USD 105.98 | USD 0 | The current share valuation price of INCY based on adjusted close was USD 105.98. The average price that INCY shares were previous bought at was USD 89.2644. The current market price is 18.7% higher than average price they were purchased at. USD 0 compared to the previous valuation of Incyte Corporation |
| IPN.PA - Ipsen SA | HOLD | 0 @ EUR 146.64 | EUR 0 | The current share valuation price of IPN.PA based on adjusted close was EUR 146.64. The average price that IPN.PA shares were previous bought at was EUR 135.278. The current market price is 8.4% higher than average price they were purchased at. The value of the holding in IPN.PA has increased by EUR 6,826 (USD $7,880) compared to the previous valuation of Ipsen SA however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| IQV - IQVIA Holdings Inc | HOLD | 0 @ USD 213.05 | USD 0 | The current share valuation price of IQV based on adjusted close was USD 213.05. The average price that IQV shares were previous bought at was USD 200.321. The current market price is 6.4% higher than average price they were purchased at. The value of the holding in IQV has increased by USD 130,388 compared to the previous valuation of IQVIA Holdings Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| ISRG - Intuitive Surgical Inc | HOLD | 0 @ USD 576.2 | USD 0 | The current share valuation price of ISRG based on adjusted close was USD 576.2. The average price that ISRG shares were previous bought at was USD 530.349. The current market price is 8.6% higher than average price they were purchased at. The value of the holding in ISRG has increased by USD 320,306 compared to the previous valuation of Intuitive Surgical Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| JNJ - Johnson & Johnson | HOLD | 0 @ USD 188.41 | USD 0 | The current share valuation price of JNJ based on adjusted close was USD 188.41. The average price that JNJ shares were previous bought at was USD 167.147. The current market price is 12.7% higher than average price they were purchased at. The value of the holding in JNJ has increased by USD 262,053 compared to the previous valuation of Johnson & Johnson however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| LH - Laboratory Corporation of America Holdings | HOLD | 0 @ USD 261.13 | USD 0 | The current share valuation price of LH based on adjusted close was USD 261.13. The average price that LH shares were previous bought at was USD 263.732. The current market price is -1.0% lower than average price they were purchased at. The value of the holding in LH has increased by USD 14,028 compared to the previous valuation of Laboratory Corporation of America Holdings however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| LLY - Eli Lilly and Company | HOLD | 0 @ USD 966.64 | USD 0 | The current share valuation price of LLY based on adjusted close was USD 966.64. The average price that LLY shares were previous bought at was USD 825.812. The current market price is 17.1% higher than average price they were purchased at. The value of the holding in LLY has increased by USD 2,610,046 compared to the previous valuation of Eli Lilly and Company however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| LONN.SW - | HOLD | 0 @ CHF 662.161 | CHF 0 | The current share valuation price of LONN.SW based on adjusted close was CHF 662.161. The average price that LONN.SW shares were previous bought at was CHF 676.676. The current market price is -2.1% lower than average price they were purchased at. The value of the holding in LONN.SW has increased by CHF 4,458 (USD $5,524) compared to the previous valuation of however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| MCK - McKesson Corporation | HOLD | 0 @ USD 859.37 | USD 0 | The current share valuation price of MCK based on adjusted close was USD 859.37. The average price that MCK shares were previous bought at was USD 773.946. The current market price is 11.0% higher than average price they were purchased at. The value of the holding in MCK has increased by USD 151,895 compared to the previous valuation of McKesson Corporation however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| MDT - Medtronic PLC | HOLD | 0 @ USD 92.66 | USD 0 | The current share valuation price of MDT based on adjusted close was USD 92.66. The average price that MDT shares were previous bought at was USD 91.6287. The current market price is 1.1% higher than average price they were purchased at. The value of the holding in MDT has increased by USD 12,409 compared to the previous valuation of Medtronic PLC however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| MOH - MOH | HOLD | 0 @ USD 140.9 | USD 0 | The current share valuation price of MOH based on adjusted close was USD 140.9. The average price that MOH shares were previous bought at was USD 201.322. The current market price is -30.0% lower than average price they were purchased at. The value of the holding in MOH has fallen by USD 163,483 compared to the previous valuation of MOH |
| MOH - LVMH Moët Hennessy - Louis Vuitton Société Européenne | HOLD | 0 @ USD 140.9 | USD 0 | The current share valuation price of MOH based on adjusted close was USD 140.9. The average price that MOH shares were previous bought at was USD 201.322. The current market price is -30.0% lower than average price they were purchased at. The value of the holding in MOH has fallen by USD 163,483 compared to the previous valuation of LVMH Moët Hennessy - Louis Vuitton Société Européenne |
| MRK - Marks Electrical Group PLC | HOLD | 0 @ USD 86.75 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 86.75. The average price that MRK shares were previous bought at was USD 89.6219. The current market price is -3.2% lower than average price they were purchased at. The value of the holding in MRK has increased by USD 66,296 compared to the previous valuation of Marks Electrical Group PLC however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| MRK - Merck & Company Inc | HOLD | 0 @ USD 86.75 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 86.75. The average price that MRK shares were previous bought at was USD 89.6219. The current market price is -3.2% lower than average price they were purchased at. The value of the holding in MRK has increased by USD 66,296 compared to the previous valuation of Merck & Company Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| MRK.DE - Merck KGaA | HOLD | 0 @ EUR 126.665 | EUR 0 | The current share valuation price of MRK.DE based on adjusted close was EUR 126.665. The average price that MRK.DE shares were previous bought at was EUR 130.82. The current market price is -3.2% lower than average price they were purchased at. The value of the holding in MRK.DE has increased by EUR 10 (USD $12) compared to the previous valuation of Merck KGaA however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| MTD - Mettler-Toledo International Inc | HOLD | 0 @ USD 1432.57 | USD 0 | The current share valuation price of MTD based on adjusted close was USD 1432.57. The average price that MTD shares were previous bought at was USD 1324.02. The current market price is 8.2% higher than average price they were purchased at. The value of the holding in MTD has fallen by USD 2,807 compared to the previous valuation of Mettler-Toledo International Inc |
| MTD - AMUNDI EUR GOV 710 | HOLD | 0 @ USD 1432.57 | USD 0 | The current share valuation price of MTD based on adjusted close was USD 1432.57. The average price that MTD shares were previous bought at was USD 1324.02. The current market price is 8.2% higher than average price they were purchased at. The value of the holding in MTD has fallen by USD 2,807 compared to the previous valuation of AMUNDI EUR GOV 710 |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 150.02 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 150.02. The average price that NBIX shares were previous bought at was USD 140.876. The current market price is 6.5% higher than average price they were purchased at. The value of the holding in NBIX has fallen by USD 5,137 compared to the previous valuation of Neurocrine Biosciences Inc |
| NOVN.SW - | HOLD | 0 @ CHF 126.728 | CHF 0 | The current share valuation price of NOVN.SW based on adjusted close was CHF 126.728. The average price that NOVN.SW shares were previous bought at was CHF 122.389. The current market price is 3.5% higher than average price they were purchased at. The value of the holding in NOVN.SW has fallen by CHF 4,745 (USD $5,879) compared to the previous valuation of |
| NOVO-B.CO - Novo Nordisk A/S | HOLD | 0 @ DKK 45.5698 | DKK 0 | The current share valuation price of NOVO-B.CO based on adjusted close was DKK 45.5698. The average price that NOVO-B.CO shares were previous bought at was DKK 56.1956. The current market price is -18.9% lower than average price they were purchased at. The value of the holding in NOVO-B.CO has increased by DKK 141,816 (USD $21,924) compared to the previous valuation of Novo Nordisk A/S however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| NTRA - Natera Inc | HOLD | 0 @ USD 206.63 | USD 0 | The current share valuation price of NTRA based on adjusted close was USD 206.63. The average price that NTRA shares were previous bought at was USD 170.421. The current market price is 21.2% higher than average price they were purchased at. The value of the holding in NTRA has increased by USD 21,335 compared to the previous valuation of Natera Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| ORNBV.HE - Orion Oyj | HOLD | 0 @ EUR 66.8542 | EUR 0 | The current share valuation price of ORNBV.HE based on adjusted close was EUR 66.8542. The average price that ORNBV.HE shares were previous bought at was EUR 67.2304. The current market price is -0.6% lower than average price they were purchased at. The value of the holding in ORNBV.HE has increased by EUR 4,733 (USD $5,464) compared to the previous valuation of Orion Oyj however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| PFE - Pfizer Inc | HOLD | 0 @ USD 24.39 | USD 0 | The current share valuation price of PFE based on adjusted close was USD 24.39. The average price that PFE shares were previous bought at was USD 24.6374. The current market price is -1.0% lower than average price they were purchased at. The value of the holding in PFE has fallen by USD 8,429 compared to the previous valuation of Pfizer Inc |
| PHIA.AS - Koninklijke Philips NV | HOLD | 0 @ EUR 28.2081 | EUR 0 | The current share valuation price of PHIA.AS based on adjusted close was EUR 28.2081. The average price that PHIA.AS shares were previous bought at was EUR 26.5931. The current market price is 6.1% higher than average price they were purchased at. The value of the holding in PHIA.AS has increased by EUR 1,780 (USD $2,055) compared to the previous valuation of Koninklijke Philips NV however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| PME.AX - | HOLD | 0 @ AUD 167.963 | AUD 0 | The current share valuation price of PME.AX based on adjusted close was AUD 167.963. The average price that PME.AX shares were previous bought at was AUD 181.054. The current market price is -7.2% lower than average price they were purchased at. The value of the holding in PME.AX has increased by AUD 6,441 (USD $4,188) compared to the previous valuation of however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| PODD - Insulet Corporation | HOLD | 0 @ USD 320.35 | USD 0 | The current share valuation price of PODD based on adjusted close was USD 320.35. The average price that PODD shares were previous bought at was USD 313.923. The current market price is 2.0% higher than average price they were purchased at. The value of the holding in PODD has increased by USD 742 compared to the previous valuation of Insulet Corporation however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| QIA.DE - QIAGEN NV | HOLD | 0 @ EUR 43.1435 | EUR 0 | The current share valuation price of QIA.DE based on adjusted close was EUR 43.1435. The average price that QIA.DE shares were previous bought at was EUR 45.509. The current market price is -5.2% lower than average price they were purchased at. The value of the holding in QIA.DE has fallen by EUR 5,300 (USD $6,118) compared to the previous valuation of QIAGEN NV |
| REC.MI - Recordati Industria Chimica e Farmaceutica SpA | HOLD | 0 @ EUR 58.1366 | EUR 0 | The current share valuation price of REC.MI based on adjusted close was EUR 58.1366. The average price that REC.MI shares were previous bought at was EUR 58.4047. The current market price is -0.5% lower than average price they were purchased at. The value of the holding in REC.MI has increased by EUR 2,771 (USD $3,199) compared to the previous valuation of Recordati Industria Chimica e Farmaceutica SpA however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| REGN - Regeneron Pharmaceuticals Inc | HOLD | 0 @ USD 654.74 | USD 0 | The current share valuation price of REGN based on adjusted close was USD 654.74. The average price that REGN shares were previous bought at was USD 594.545. The current market price is 10.1% higher than average price they were purchased at. The value of the holding in REGN has fallen by USD 8,707 compared to the previous valuation of Regeneron Pharmaceuticals Inc |
| RMD - ResMed Inc | HOLD | 0 @ USD 250.1 | USD 0 | The current share valuation price of RMD based on adjusted close was USD 250.1. The average price that RMD shares were previous bought at was USD 264.031. The current market price is -5.3% lower than average price they were purchased at. The value of the holding in RMD has fallen by USD 4,291 compared to the previous valuation of ResMed Inc |
| RO.SW - | HOLD | 0 @ CHF 359.601 | CHF 0 | The current share valuation price of RO.SW based on adjusted close was CHF 359.601. The average price that RO.SW shares were previous bought at was CHF 341.923. The current market price is 5.2% higher than average price they were purchased at. The value of the holding in RO.SW has increased by CHF 124,479 (USD $154,232) compared to the previous valuation of however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| ROG.SW - | HOLD | 0 @ CHF 345.837 | CHF 0 | The current share valuation price of ROG.SW based on adjusted close was CHF 345.837. The average price that ROG.SW shares were previous bought at was CHF 325.693. The current market price is 6.2% higher than average price they were purchased at. The value of the holding in ROG.SW has increased by CHF 303,971 (USD $376,626) compared to the previous valuation of however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| RPRX - Royalty Pharma Plc | HOLD | 0 @ USD 38.54 | USD 0 | The current share valuation price of RPRX based on adjusted close was USD 38.54. The average price that RPRX shares were previous bought at was USD 36.5322. The current market price is 5.5% higher than average price they were purchased at. The value of the holding in RPRX has fallen by USD 161 compared to the previous valuation of Royalty Pharma Plc |
| RVTY - Revvity Inc. | HOLD | 0 @ USD 92.2799 | USD 0 | The current share valuation price of RVTY based on adjusted close was USD 92.2799. The average price that RVTY shares were previous bought at was USD 92.115. The current market price is 0.2% higher than average price they were purchased at. The value of the holding in RVTY has increased by USD 4,684 compared to the previous valuation of Revvity Inc. however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| SAN.PA - Sanofi SA | HOLD | 0 @ EUR 100.235 | EUR 0 | The current share valuation price of SAN.PA based on adjusted close was EUR 100.235. The average price that SAN.PA shares were previous bought at was EUR 98.8748. The current market price is 1.4% higher than average price they were purchased at. The value of the holding in SAN.PA has increased by EUR 30,869 (USD $35,635) compared to the previous valuation of Sanofi SA however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| SDZ.SW - | HOLD | 0 @ CHF 66.7618 | CHF 0 | The current share valuation price of SDZ.SW based on adjusted close was CHF 66.7618. The average price that SDZ.SW shares were previous bought at was CHF 57.1581. The current market price is 16.8% higher than average price they were purchased at. The value of the holding in SDZ.SW has increased by CHF 9,415 (USD $11,665) compared to the previous valuation of however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| SHL.AX - | HOLD | 0 @ AUD 13.7629 | AUD 0 | The current share valuation price of SHL.AX based on adjusted close was AUD 13.7629. The average price that SHL.AX shares were previous bought at was AUD 14.8355. The current market price is -7.2% lower than average price they were purchased at. The value of the holding in SHL.AX has increased by AUD 3,318 (USD $2,157) compared to the previous valuation of however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| SHL.DE - Siemens Healthineers AG | HOLD | 0 @ EUR 50.0656 | EUR 0 | The current share valuation price of SHL.DE based on adjusted close was EUR 50.0656. The average price that SHL.DE shares were previous bought at was EUR 53.8357. The current market price is -7.0% lower than average price they were purchased at. The value of the holding in SHL.DE has fallen by EUR 218 (USD $252) compared to the previous valuation of Siemens Healthineers AG |
| SIG.AX - | HOLD | 0 @ AUD 2.03314 | AUD 0 | The current share valuation price of SIG.AX based on adjusted close was AUD 2.03314. The average price that SIG.AX shares were previous bought at was AUD 1.9959. The current market price is 1.9% higher than average price they were purchased at. The value of the holding in SIG.AX has increased by AUD 2,827 (USD $1,838) compared to the previous valuation of however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| SN.L - Smith & Nephew PLC | HOLD | 0 @ GBP 16.7118 | GBP 0 | The current share valuation price of SN.L based on adjusted close was GBP 16.7118. The average price that SN.L shares were previous bought at was GBP 17.6091. The current market price is -5.1% lower than average price they were purchased at. The value of the holding in SN.L has increased by GBP 886 (USD $1,164) compared to the previous valuation of Smith & Nephew PLC however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| SOBI.ST - | HOLD | 0 @ SEK 34.4801 | SEK 0 | The current share valuation price of SOBI.ST based on adjusted close was SEK 34.4801. The average price that SOBI.ST shares were previous bought at was SEK 31.2771. The current market price is 10.2% higher than average price they were purchased at. The value of the holding in SOBI.ST has increased by SEK 2,999 (USD $314) compared to the previous valuation of however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| SOLV - Solventum Corp. | HOLD | 0 @ USD 71.79 | USD 0 | The current share valuation price of SOLV based on adjusted close was USD 71.79. The average price that SOLV shares were previous bought at was USD 70.6839. The current market price is 1.6% higher than average price they were purchased at. The value of the holding in SOLV has increased by USD 1,012 compared to the previous valuation of Solventum Corp. however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| SOON.SW - | HOLD | 0 @ CHF 262.137 | CHF 0 | The current share valuation price of SOON.SW based on adjusted close was CHF 262.137. The average price that SOON.SW shares were previous bought at was CHF 278.783. The current market price is -6.0% lower than average price they were purchased at. The value of the holding in SOON.SW has fallen by CHF 8,548 (USD $10,591) compared to the previous valuation of |
| SRT3.DE - Sartorius AG | HOLD | 0 @ EUR 259.796 | EUR 0 | The current share valuation price of SRT3.DE based on adjusted close was EUR 259.796. The average price that SRT3.DE shares were previous bought at was EUR 255.58. The current market price is 1.6% higher than average price they were purchased at. The value of the holding in SRT3.DE has increased by EUR 29,439 (USD $33,984) compared to the previous valuation of Sartorius AG however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| STE - STERIS plc | HOLD | 0 @ USD 264.01 | USD 0 | The current share valuation price of STE based on adjusted close was USD 264.01. The average price that STE shares were previous bought at was USD 226.428. The current market price is 16.6% higher than average price they were purchased at. The value of the holding in STE has increased by USD 9,280 compared to the previous valuation of STERIS plc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| STMN.SW - | HOLD | 0 @ CHF 121.173 | CHF 0 | The current share valuation price of STMN.SW based on adjusted close was CHF 121.173. The average price that STMN.SW shares were previous bought at was CHF 115.787. The current market price is 4.7% higher than average price they were purchased at. The value of the holding in STMN.SW has increased by CHF 2,549 (USD $3,158) compared to the previous valuation of however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| SYK - Stryker Corporation | HOLD | 0 @ USD 355.02 | USD 0 | The current share valuation price of SYK based on adjusted close was USD 355.02. The average price that SYK shares were previous bought at was USD 370.433. The current market price is -4.2% lower than average price they were purchased at. The value of the holding in SYK has fallen by USD 7,076 compared to the previous valuation of Stryker Corporation |
| TEVA - Teva Pharma Industries Ltd ADR | HOLD | 0 @ USD 24.26 | USD 0 | The current share valuation price of TEVA based on adjusted close was USD 24.26. The average price that TEVA shares were previous bought at was USD 18.6802. The current market price is 29.9% higher than average price they were purchased at. The value of the holding in TEVA has increased by USD 7,101 compared to the previous valuation of Teva Pharma Industries Ltd ADR however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| TMO - Time Out Group plc | HOLD | 0 @ USD 576.35 | USD 0 | The current share valuation price of TMO based on adjusted close was USD 576.35. The average price that TMO shares were previous bought at was USD 475.692. The current market price is 21.2% higher than average price they were purchased at. The value of the holding in TMO has increased by USD 82,918 compared to the previous valuation of Time Out Group plc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| UCB.BR - UCB SA | HOLD | 0 @ EUR 258.873 | EUR 0 | The current share valuation price of UCB.BR based on adjusted close was EUR 258.873. The average price that UCB.BR shares were previous bought at was EUR 207.476. The current market price is 24.8% higher than average price they were purchased at. The value of the holding in UCB.BR has fallen by EUR 84,377 (USD $97,404) compared to the previous valuation of UCB SA |
| UNH - UnitedHealth Group Incorporated | HOLD | 0 @ USD 321.58 | USD 0 | The current share valuation price of UNH based on adjusted close was USD 321.58. The average price that UNH shares were previous bought at was USD 437.234. The current market price is -26.5% lower than average price they were purchased at. The value of the holding in UNH has fallen by USD 160,709 compared to the previous valuation of UnitedHealth Group Incorporated |
| UTHR - United Therapeutics Corporation | HOLD | 0 @ USD 453.93 | USD 0 | The current share valuation price of UTHR based on adjusted close was USD 453.93. The average price that UTHR shares were previous bought at was USD 420.31. The current market price is 8.0% higher than average price they were purchased at. The value of the holding in UTHR has increased by USD 4,448 compared to the previous valuation of United Therapeutics Corporation however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| VEEV - Veeva Systems Inc Class A | HOLD | 0 @ USD 295.75 | USD 0 | The current share valuation price of VEEV based on adjusted close was USD 295.75. The average price that VEEV shares were previous bought at was USD 285.857. The current market price is 3.5% higher than average price they were purchased at. The value of the holding in VEEV has increased by USD 24,467 compared to the previous valuation of Veeva Systems Inc Class A however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| VRTX - Vertex Pharmaceuticals Inc | HOLD | 0 @ USD 421.2 | USD 0 | The current share valuation price of VRTX based on adjusted close was USD 421.2. The average price that VRTX shares were previous bought at was USD 422.051. The current market price is -0.2% lower than average price they were purchased at. The value of the holding in VRTX has increased by USD 425,705 compared to the previous valuation of Vertex Pharmaceuticals Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| WAT - Waters Corporation | HOLD | 0 @ USD 376.57 | USD 0 | The current share valuation price of WAT based on adjusted close was USD 376.57. The average price that WAT shares were previous bought at was USD 338.317. The current market price is 11.3% higher than average price they were purchased at. The value of the holding in WAT has increased by USD 99,201 compared to the previous valuation of Waters Corporation however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| WAT - MULETFWATIMETFP | HOLD | 0 @ USD 376.57 | USD 0 | The current share valuation price of WAT based on adjusted close was USD 376.57. The average price that WAT shares were previous bought at was USD 338.317. The current market price is 11.3% higher than average price they were purchased at. The value of the holding in WAT has increased by USD 99,201 compared to the previous valuation of MULETFWATIMETFP however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| WST - West Pharmaceutical Services Inc | HOLD | 0 @ USD 275.47 | USD 0 | The current share valuation price of WST based on adjusted close was USD 275.47. The average price that WST shares were previous bought at was USD 267.944. The current market price is 2.8% higher than average price they were purchased at. The value of the holding in WST has increased by USD 6,548 compared to the previous valuation of West Pharmaceutical Services Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| ZBH - Zimmer Biomet Holdings Inc | HOLD | 0 @ USD 88.7299 | USD 0 | The current share valuation price of ZBH based on adjusted close was USD 88.7299. The average price that ZBH shares were previous bought at was USD 98.4616. The current market price is -9.9% lower than average price they were purchased at. The value of the holding in ZBH has increased by USD 951 compared to the previous valuation of Zimmer Biomet Holdings Inc however if the holding was sold on 2025-11-10 this would crystalise an overall loss. |
| ZTS - Zoetis Inc | HOLD | 0 @ USD 119.79 | USD 0 | The current share valuation price of ZTS based on adjusted close was USD 119.79. The average price that ZTS shares were previous bought at was USD 141.646. The current market price is -15.4% lower than average price they were purchased at. The value of the holding in ZTS has fallen by USD 38,042 compared to the previous valuation of Zoetis Inc |